Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Tuesday, July 25, 2017

GlaxoSmithKline's new CEO prepares to trim drug pipeline

We need to get away from the dependency on drug companies providing research and the US government funding research.

Biopharmaceutical companies have 215 heart disease/stroke drugs in R&D pipeline June of 2013

You'll have to hope some made it to stroke use. I have no idea who you could ask for confirmation. 

 

With a defined stroke strategy getting foundation grants and individual donors to step up and fund such research would be damned easy.  Asking for general funding for stupid stroke association press release funding is complete insanity. Asking for funding to solve glutamate poisoning in the neuronal cascade of death would be a concrete proposal people and foundations could get behind. I.E, 'I helped solve the glutamate poisoning piece of stroke neuron death'. You could send out certificates of appreciation suitable to being framed. This is so fucking easy to solve the funding problem but will require destroying our fucking failures of stroke associations and replacing them with a great stroke association. 


GlaxoSmithKline's new CEO prepares to trim drug pipeline


Reuters Health News
GlaxoSmithKline's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs.
Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.
That means axing or licensing out some experimental drugs in non-core therapy areas, while boosting investment - as well as potential early-stage acquisitions - in the most promising fields, according to company insiders.
Even after recent expansion of GSK's vaccines and consumer health units, pharmaceuticals still account for nearly 70 percent of group operating profits.
Yet while GSK now has leading positions in vaccines and consumer health, it has a lacklustre record in prescription medicines and has not come up with the kind of multibillion-dollar products launched by big pharma rivals in recent years.
Walmsley will flesh out her plans for overhauling drug research when she presents second quarter results on July 26.
She has already flagged her readiness to scrap products not generating sufficient value with plans to sell off malted drink Horlicks in Britain and MaxiNutrition, while considering the disposal of older antibiotics.
Describing the approach after presenting her first set of results in April, she said: "We will need to be switching off some areas."
The goal is to sharpen what is currently one of the more diverse drug pipelines in the pharmaceuticals industry, spread across a wide range of therapy areas.
In some fields, like respiratory and HIV medicine, GSK has a clear leading position. But it lags in others such as cardiovascular, rare diseases and diabetes, and some investors worry it has been spreading its R and D budget too thinly.
The result can be sub-optimal product launches, such as Tanzeum for type 2 diabetes, which has generated disappointing sales after GSK launched the injection behind rival medicines from Novo Nordisk and AstraZeneca.
Others, like a novel pill for heart disease, have flopped in tests even before getting to market, while its lupus drug Benlysta has failed to hit initial blockbuster sales forecasts, despite GSK spending $3 billion to buy the firm that invented it.
In prioritizing areas where GSK has deep scientific and market expertise, Walmsley wants the R and D and commercial departments at GSK to work together much more closely in future.
In some ways, GSK looks set to follow in the footsteps of its smaller British rival AstraZeneca, which has divested a large number of non-core drug projects recently as it concentrates on core areas like cancer.Significantly, former AstraZeneca executive Luke Miels will be a key lieutenant for Walmsley during the shake-up. He will join GSK in September, several months later than planned due to a legal tussle with his former employer.
Analysts and investors have welcomed the idea of rationalizing GSK's R and D, but caution it will be a long haul.
"It’s a company which has struggled to do what you would hope a pharmaceutical company would do, which is do the R and D and successfully get the products through," said Insight Investment fund manager Tim Rees.
Rees said an R and D revamp made sense but it would take 5-7 years to yield results.
Fortunately, Walmsley has a window to make the changes. GSK is not expecting its next wave of new drugs until after 2020 and also has no significant patent expiries, barring the imminent loss of protection on lung drug Advair, until 2026.
—Ben Hirschler

No comments:

Post a Comment